Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Zevra Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners across 2 art units, so the portfolio follows separate examination paths.
AULAKH, CHARANJIT is the busiest examiner with 1 pending action. Counsel should prepare matter-specific responses while coordinating terminology and support for the pharmaceutical claim set.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.8% | -14.4% |
| SEAMAN, D MARGARET M | 1 | 76.7% | +8.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18787677 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18787677 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | AULAKH, CHARANJIT | 1621 | §102§112 | Non-Final OA | — | Pending | Jul 29, 2024 |
| 18355983 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | SEAMAN, D MARGARET M | 1625 | DP | Final Rejection | — | Pending | Jul 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZevra Therapeutics Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Charanjit Aulakh has the most, with 1 of Zevra Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.